**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 88308

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Post-operative morbidity after neoadjuvant chemotherapy and resection for gallbladder cancer: A national surgical quality improvement program analysis**

Kim M *et al.* NSQIP Outcomes of NACT for GBC

Minha Kim, Stephanie Stroever, Krist Aploks, Alexander Ostapenko, Xiang Da Dong, Ramanathan Seshadri

**Minha Kim, Krist Aploks, Alexander Ostapenko,** Department of General Surgery, Danbury Hospital, Danbury, CT 06810, United States

**Stephanie Stroever,** Department of Research and Innovation, Nuvance Health, Danbury, CT 06810, United States

**Xiang Da Dong, Ramanathan Seshadri,** Division of Surgical Oncology/Hepato-Pancreato-Biliary Surgery, Danbury Hospital, Danbury, CT 06810, United States

**Author contributions:** Kim, M, Aploks K, Ostapenko A, Dong X, and Seshadri R contributed to the conceptualization of the project; Kim M, Stroever S, Aploks K, Ostapenko A, Dong X, and Seshadri R contributed to the methodology and validation of the data; Stroever S conducted the formal statistical analyses; Kim, M, Aploks K, Ostapenko A prepared the original manuscript; Kim, M, Aploks K, Ostapenko A, Dong X, and Seshadri R contributed to the final draft revision and edition; Dong X, and Seshadri R supervised the project.

**Corresponding author: Ramanathan Seshadri, MD, Surgeon,** Division of Surgical Oncology/Hepato-Pancreato-Biliary Surgery, Danbury Hospital, 95 Locus Avenue, Danbury, CT 06810, United States. ramanathan.seshadri@nuvancehealth.org

**Received:** September 23, 2023

**Revised:** November 27, 2023

**Accepted:** December 18, 2023

**Published online:**

**Abstract**

BACKGROUND

Gallbladder cancer is the most common malignancy of the biliary tract. Neoadjuvant chemotherapy (NACT) has improved overall survival by enabling R0 resection. Currently, there is no consensus of guidelines for neoadjuvant therapy in gallbladder cancer. As investigations continue to analyze the regimen and benefit of NACT for ongoing care of gallbladder cancer patients, we examined American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database to determine if there was higher morbidity among the neoadjuvant group within the 30-day post-operative period. We hypothesized patients who underwent NACT were more likely to have higher post-operative morbidity.

AIM

To investigate the 30-day post-operative morbidity outcomes between patients who received NACT and underwent surgery and patients who only had surgery.

METHODS

A retrospective analysis of the targeted hepatectomy NSQIP data between 2015 and 2019 was performed to determine if NACT in gallbladder cancer increased the risk for post-operative morbidity (bile leak, infection rate, rate of converting to open surgery, *etc.*) compared to the group who only had surgery. To calculate the odds ratio for the primary and secondary outcomes, a crude logistic regression was performed.

RESULTS

Of the 452 patients, 52 patients received NACT prior to surgery. There were no statistically significant differences in the odds of morbidity between the two groups, including bile leak [odds ratio (OR), 0.69; 95% confidence interval (95%CI), 0.16-2.10; *P* = 0.55], superficial wound infection (OR, 0.58; 95%CI 0.03-3.02; *P* = 0.61), and organ space wound infection (OR, 0.63; 95%CI, 0.18-1.63; *P* = 0.61).

CONCLUSION

There was no significant difference in the risk of 30-day post-operative morbidity between the NACT and surgery group and the surgery only group.

**Key Words:** Gallbladder cancer; Neoadjuvant chemotherapy; Radical cholecystectomy; National Surgery Quality Improvement Program; Postoperative outcome

Kim M, Stroever S, Aploks K, Ostapenko A, Dong XD, Seshadri R. Post-operative morbidity after neoadjuvant chemotherapy and resection for gallbladder cancer: A national surgical quality improvement program analysis. *World J Gastrointest Surg* 2023; In press

**Core Tip:** In this retrospective study, we utilized the National Surgery Quality Improvement Program database to assess the post-operative morbidity of neoadjuvant chemotherapy (NACT) for gallbladder cancer. While the role of NACT for gallbladder cancer is being investigated, surgeons should be mindful of the potential complications patients receiving NACT may be at risk for post-operatively. Our study revealed that NACT was not associated with increased post-operative morbidity, such as bile leaks or wound infections. Although there were no increased complications, NACT should be carefully evaluated for each individual patient due to the inherent side effects of chemotherapy.

**INTRODUCTION**

Gallbladder cancer is the sixth most common gastrointestinal malignancy in the United States with an incidence of 1.13 cases per 100000[1]. Current guidelines recommend cholecystectomy for stage T1a and radical cholecystectomy (cholecystectomy, segment IVb and V liver resection, regional lymphadenectomy) for T1b or greater. neoadjuvant chemotherapy (NACT) may be considered for locoregional advanced disease to prevent rapid progression of the cancer and improve rates of R0 and R1 resection[2]. There are currently no consensus guidelines in regards to neoadjuvant therapy for gallbladder cancer.

There have been few clinical studies that have looked into the effects of neoadjuvant therapy, including chemotherapy and radiation, for gallbladder cancer to determine survival benefit and rate for curative resections[3-6]. A 2019 review of six retrospective and two prospective studies showed that of the 40% (approximately 189 out of 474 patients) of patients who had received neoadjuvant therapy, 92.5% had R0 resections and the median overall survival for those patients ranged from 18.5 to 50.1 months[6]. Since the studies that were reviewed lacked comparison between the treatments, the authors of the review concluded that there was not sufficient data to support the use of neoadjuvant therapy for gallbladder carcinoma[1]. The debate whether NACT is beneficial is ongoing and there is a current trial[7] in place to further study the overall survival benefit of NACT for gallbladder carcinoma. Although, post-operative complications are not the focus of these studies and the prevalence of these complications are not fully documented, it would be beneficial for surgeons to be aware of the possible complications in the post-operative setting and whether NACT impacts the patients’ overall recovery. From the clinical studies that have been reviewed, the most commonly documented post-operative complication is bile leak[4,8].

The goal of this study was to use the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) data to identify post-operative morbidities in the setting of NACT as opposed to those who had undergone surgery upfront and determine if there is a significant risk difference between the two groups. This data may assist surgeons in determining whether NACT would be beneficial for their patients prior to undergoing surgery with regards to perioperative morbidity.

**MATERIALS AND METHODS**

A retrospective analysis of the ACS NSQIP participant use data files was performed. These files include data from participating institutions across the United States based on a robust sampling strategy described previously[9]. Procedure-targeted hepatectomy data files for 2015-2019 were obtained. We included all patients 18 years and older with a diagnosis of gallbladder cancer and excluded patients that underwent emergent surgery, had viral hepatitis B and/or C, or unknown hepatitis status.

The primary outcome for this study was bile leakage within 30 d of surgery. Secondary outcomes were blood transfusion, on ventilator greater than 48 h, length of intensive care unit stay, readmission within 30 d, superficial incisional wound infection, organ space wound infection, secondary intervention, conversion rate to open, and need for biliary reconstruction.

Numerous covariates and potential confounders were included in our analyses. We included demographic variables including age, sex, race, and ethnicity. The following comorbidities: diabetes, history of smoking within one year of surgery, history of hypertension requiring medication, steroid use for chronic condition, and greater than 10 percent loss of body weight in the last six months.

We also included procedure-specific variables including placement of a biliary stent prior to surgery and cancer staging. Pre-operative laboratory values for serum albumin, total bilirubin, blood urea nitrogen, serum creatinine, and international normalized ratio were also examined.

***Statistical methods***

Statistical analyses were performed using R (R Foundation for Statistical Computing, Vienna, Austria) and StataSE version 16 (StataCorps LLC, College Station, Texas). Missing data was accommodated with listwise deletion in crude and multivariable analyses. We calculated descriptive statistics using mean ± SD for continuous variables and number with percentage for categorical variables. To determine group differences given exposure group, we used Fisher’s exact test (cell counts less than 5), Pearson’s chi-squared test (cell counts greater than 5), and Wilcoxon rank sum test for non-normally distributed continuous variables.

Model-building strategies were used to determine the difference in the odds of bile leakage given exposure NACT while adjusting for potential confounders. We performed crude logistic regression for all variables with bile leakage as the outcome, only including variables that were statistically significantly associated with the outcome in the final multivariable model (*P* < 0.05 established *a priori*). Crude logistic regression was performed for all secondary dichotomous outcomes and Poisson regression for length of stay. There were no statistically significant differences in secondary outcomes given exposure to NACT. Thus, we did not perform any further testing on these outcomes.

***Post hoc* analyses**

Bivariate analyses were performed to further explore the association between NACT and selected outcomes by tumor stage. We independently assessed differences in outcomes given exposure to NACT in stage T2 patients, then again in stage T3/T4 patients. We used Pearson’s chi-squared test and Fisher’s exact test for dichotomous outcomes and Wilcoxon rank sum test for length of stay. Again, we selected α = 0.05 for these analyses.

**RESULTS**

After exclusions, we included 452 patients in our sample (Table 1). Seventy percent of patients were tumor stage II, III, or IV though approximately 17% had unknown T stage. Nodal stage was equally distributed across all categories, and the majority were either M0/Mx or had unknown metastasis. The majority of patients did not undergo NACT (88.5%), and there were no statistically significant differences across exposure group for any of the covariates except pre-operative total bilirubin (*P* < 0.01), which is not clinically meaningful.

Ten percent of patients had bile leakage with only three of those patients having had NACT. On univariate logistic regression, the odds of bile leakage were not statistically significantly different given age, sex, race, ethnicity, diabetes status, smoking, steroid use for a chronic condition, or > 10% loss of body weight in the last six months (*P* > 0.05).

There was a statistically significant difference in the odds of bile leakage among patients with a biliary stent placed preoperatively [odds ratio (OR) = 3.66, 95% confidence interval (95%CI) = 1.73, 7.41, *P* < 0.01]. There was no statistically significant difference in the odds of bile leakage for nodal stages 1/2 or Nx/unknown compared to N0 (*P* > 0.05), nor was there a difference for metastasis stage 1 or unknown compared to M0/Mx (*P* > 0.05).

Based on these results, we included NACT and pre-operative placement of a biliary stent in our multivariable logistic regression model. We also included race and ethnicity, as they are commonly hypothesized confounders, and pre-operative bilirubin, which was different across exposure groups. We found there was not a statistically significant difference in the odds of bile leakage among patients who received NACT after controlling for potential confounders (OR = 0.69, 95%CI = 0.16, 2.10, *P* = 0.55).

The median length of stay for all patients regardless of exposure group was five hospital days. Few patients required post-operative mechanical ventilation greater than 48 h (1.3%), while the most common outcome was biliary reconstruction (19.2%). Of note, 21.2% of patients who had NACT required a blood transfusion within 72 h of surgery.

***Secondary outcomes and Post hoc analyses***

On univariate logistic regression, there were no statistically significant differences in the odds of any of the secondary outcomes given exposure to NACT (Table 2). The hospital length of stay also did not differ significantly on Poisson regression (*P* = 0.12). Patients with stage T2 cancer that underwent NACT did not experience a bile leakage following surgery. There were no significant differences in the other outcomes given NACT among patients with T2 cancer either (*P* >0.05).

Approximately 20% of patients with stage T3/T4 gallbladder cancer experienced a bile leakage following surgery. However, there was not a statistically significant difference given exposure to NACT (Fisher’s exact test, *P* = 0.37). Only two patients in that group experienced a bile leakage. Similar to stage T2, there were no statistically significant differences in any of the other outcomes among stage T3/T4 patients given exposure to NACT.

**DISCUSSION**

According the to the National Comprehensive Cancer Network guidelines, NACT is considered in patients with gallbladder cancer if there is locoregional advanced disease or if a patient has an unresectable disease. There is no preferred regimen for NACT since there is limited clinical data to define a standard regimen[2]. Patients who undergo NACT have commonly received gemcitabine and cisplatin. This regimen proved to have significant survival benefit in advanced biliary cancer and therefore has been implemented in patients with gallbladder cancer[10].

The goal of surgery for gallbladder cancer is to obtain R0 resection for potential curative treatment[11]. Clinical trials have shown that NACT improves rates of R0 resection in locally advanced gallbladder cancer[1,4,5]. Compared to R0 resection, R1 resection has worse survival[12,13]. Patients with R1 resection may undergo adjuvant therapy for improved survival benefit[11,14-16].

De Savornin Lohman *et al*[17] evaluated the survival benefit of re-resection after incidentally found gallbladder cancer. They found that there was overall survival benefit with re-resection; however, prognosis was affected by the presence of residual disease and lymph node metastasis despite clear resection margins. Lundgren *et al*[18] also found similar results in improved survival in re-resection for pT2 and pT3 incidental gallbladder cancer and residual disease impaired survival. With residual disease, surgeons must consider if additional surgery should be performed. Further resection may not have added benefit since residual disease can be clinical equivalent to distant metastatic disease[19] and patients are at risk for further peri-operative morbidity with major hepatectomy and pancreatoduodenectomy[20-22]. The intended benefit of NACT is to improve overall survival by achieving R0 resection and to avoid further resection. However, NACT does have its own risks and complications. Aside from the direct side effects of chemotherapy, there are concerns chemotherapy can complicate surgery and increase risks for peri-operative morbidities. NSQIP allows us to evaluate potential peri-operative complications within thirty days of surgery.

The primary outcome evaluated in our study was post-operative bile leak as this was a well-documented complication in clinical studies that evaluated survival impact of NACT in gallbladder cancer[4,8]. The treatment for the bile leaks included maintaining the drain placed during surgery or percutaneous drainage. The secondary outcomes that were evaluated were readmission within thirty days of discharge, superficial incisional wound infection, organ space wound infect, and the need for secondary intervention. In our study, we found that there was no statistical significance of any of these complications between the NACT and upfront surgery group.

Although our data may provide reassurance that NACT is safe to use for the appropriate patient population without having concerns for complications in the immediate post-operative period, this data is limited by the power of the study. The power of our study is low, as there were 452 patients diagnosed with gallbladder cancer and 52 patients had undergone NACT. With a larger study sample, there could be a statistically significant difference between the NACT group and upfront surgery group indicating that NACT could increase post-operative complications. Another limitation is the definition of a bile leak. NSQIP defines a bile leak as clinical diagnosis or persistent drainage that may have required maintenance of drain on or after post operative day 3, requiring percutaneous or operative intervention, or spontaneous wound drainage. The definition does not indicate if bilirubin levels were measured to prove a bile leak. A third limitation of this study are that the ACS NSQIP Targeted Hepatectomy dataset does not capture the specific details in regards to timing of chemotherapy, the chemotherapy regimen, duration of treatment, or if patients completed a full course of treatment. The data also only captures perioperative outcomes thirty days from the index operation.

Despite these limitations, our study provides additional information and insight into the use of NACT. As further clinical trials evaluate the effect of NACT, this study should be re-evaluated to determine potential significant complications of the use of NACT in gallbladder cancer and within the post-operative period.

**CONCLUSION**

Gallbladder cancer is a rare and aggressive cancer when it is diagnosed late. Randomized controlled clinical trials are needed to validate the routine use of NACT in gallbladder cancer irrespective of their stage at presentation. Although our study shows that NACT does not increase post-operative morbidity, additional data on NACT for gallbladder cancer is needed to better understand the effect of NACT on 30-day post-operative morbidity. Until further information is available, surgeons will need to carefully evaluate the benefit and risks of NACT for patients undergoing surgical intervention.

**ARTICLE HIGHLIGHTS**

***Research background***

Gallbladder cancer is the most common malignancy of the biliary tract. There are no consensus guidelines in regards to the use of neoadjuvant chemotherapy (NACT) for gallbladder cancer. Until a standardized regimen and guidelines are implemented, surgeons need to be aware of the potential effects of NACT on post-operative outcomes.

***Research motivation***

NACT is recommended based on clinical and pathological findings. Physicians need to carefully tailor the management of gallbladder cancer to the individual patient. By being aware of the benefits and risks of NACT both pre-operative and post-operatively, physicians can make informed decisions regarding its use in gallbladder cancer.

***Research objectives***

The objective of the study was to investigate the 30-day post-operative morbidities associated with NACT in gallbladder cancer.

***Research methods***

We performed a retrospective analysis using the National Surgery Quality Improvement Program database between 2015 and 2019. Patients with gallbladder cancer were identified and divided the patients into two cohorts based on their NACT status.

***Research results***

Compared to the upfront surgery group, patients who underwent chemotherapy and surgery for gallbladder cancer did not experience worse outcome. There were no statistically significant post-operative morbidities.

***Research conclusions***

While there were no differences in the 30-day post-operative morbidities between the two cohorts, the benefits and risks of NACT should be carefully considered for patients, taking into account the potential side effects of chemotherapy.

***Research perspectives***

Further research on the effects of NACT for gallbladder cancer needs to be conducted. When more clinical data is available, the post-operative morbidities associated with NACT can be further evaluated.

**REFERENCES**

1 **Gamboa AC**, Maithel SK. The Landmark Series: Gallbladder Cancer. *Ann Surg Oncol* 2020; **27**: 2846-2858 [PMID: 32474816 DOI: 10.1245/s10434-020-08654-9]

2 **National Comprehensive Cancer Network**. Hepatobiliary Cancer (Version 5.2021). 2021. [cited March 2023]. Available from: https://www.nccn.org/professionals/physician\_gls/pdf/ hepatobiliary.pdf

3 **Goetze TO**, Bechstein WO, Bankstahl US, Keck T, Königsrainer A, Lang SA, Pauligk C, Piso P, Vogel A, Al-Batran SE. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial. *BMC Cancer* 2020; **20**: 122 [PMID: 32059704 DOI: 10.1186/s12885-020-6610-4]

4 **Chaudhari VA**, Ostwal V, Patkar S, Sahu A, Toshniwal A, Ramaswamy A, Shetty NS, Shrikhande SV, Goel M. Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer: the need to define indications. *HPB (Oxford)* 2018; **20**: 841-847 [PMID: 29706425 DOI: 10.1016/j.hpb.2018.03.008]

5 **Creasy JM**, Goldman DA, Dudeja V, Lowery MA, Cercek A, Balachandran VP, Allen PJ, DeMatteo RP, Kingham TP, D'Angelica MI, Jarnagin WR. Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. *J Am Coll Surg* 2017; **224**: 906-916 [PMID: 28216422 DOI: 10.1016/j.jamcollsurg.2016.12.058]

6 **Hakeem AR**, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review. *Eur J Surg Oncol* 2019; **45**: 83-91 [PMID: 30287098 DOI: 10.1016/j.ejso.2018.08.020]

7 **ECOG-ACRIN Cancer Research Group**.Comparison of Chemotherapy Before and After Surgery Versus Surgery Alone for Treatment of Gallbladder Cancer. [accessed 2021 Feb 24]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: [https://clinicaltrials.gov/ct2/show/](https://clinicaltrials.gov/ct2/show/NCT04559139)[NCT04559139](https://clinicaltrials.gov/ct2/show/NCT04559139) ClinicalTrials.gov Identifier: NCT04559139

8 **Engineer R**, Goel M, Chopra S, Patil P, Purandare N, Rangarajan V, Ph R, Bal M, Shrikhande S, Shrivastava SK, Mehta S. Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm. *Ann Surg Oncol* 2016; **23**: 3009-3015 [PMID: 27075323 DOI: 10.1245/s10434-016-5197-0]

9 **American College of Surgeons National Surgical Quality Improvement Program**. User Guide for the 2019 ACS NSQIP Participant Use Data File (PUF). October 2020. [cited September 2021]. Available from: chrome-extension://bocbaocobfecmglnmeaeppambideimao/pdf/viewer.html?file=https%3A%2F%2Fwww.facs.org%2Fmedia%2Fugrjcbes%2Fpeds\_nsqip\_userguide\_2019.pdf

10 **Valle J**, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 2010; **362**: 1273-1281 [PMID: 20375404 DOI: 10.1056/NEJMoa0908721]

11 **Müller BG**, De Aretxabala X, González Domingo M. A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done. *Am Soc Clin Oncol Educ Book* 2014: e165-e170 [PMID: 24857099 DOI: 10.14694/EdBook\_AM.2014.34.e165]

12 **Kim TG**. Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. *Radiat Oncol J* 2017; **35**: 359-367 [PMID: 29249117 DOI: 10.3857/roj.2017.00388]

13 **Birnbaum DJ**, Viganò L, Ferrero A, Langella S, Russolillo N, Capussotti L. Locally advanced gallbladder cancer: which patients benefit from resection? *Eur J Surg Oncol* 2014; **40**: 1008-1015 [PMID: 24246608 DOI: 10.1016/j.ejso.2013.10.014]

14 **Shroff RT**, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. *J Clin Oncol* 2019; **37**: 1015-1027 [PMID: 30856044 DOI: 10.1200/JCO.18.02178]

15 **Wang SJ**, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, Kim JS, Thomas CR Jr. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. *J Clin Oncol* 2011; **29**: 4627-4632 [PMID: 22067404 DOI: 10.1200/JCO.2010.33.8020]

16 **Ma N**, Cheng H, Qin B, Zhong R, Wang B. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. *BMC Cancer* 2015; **15**: 615 [PMID: 26337466 DOI: 10.1186/s12885-015-1617-y]

17 **de Savornin Lohman EAJ**, van der Geest LG, de Bitter TJJ, Nagtegaal ID, van Laarhoven CJHM, van den Boezem P, van der Post CS, de Reuver PR. Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease. *Ann Surg Oncol* 2020; **27**: 1132-1142 [PMID: 31741109 DOI: 10.1245/s10434-019-08074-4]

18 **Lundgren L**, Muszynska C, Ros A, Persson G, Gimm O, Andersson B, Sandström P. Management of incidental gallbladder cancer in a national cohort. *Br J Surg* 2019; **106**: 1216-1227 [PMID: 31259388 DOI: 10.1002/bjs.11205]

19 **Butte JM**, Kingham TP, Gönen M, D'Angelica MI, Allen PJ, Fong Y, DeMatteo RP, Jarnagin WR. Residual disease predicts outcomes after definitive resection for incidental gallbladder cancer. *J Am Coll Surg* 2014; **219**: 416-429 [PMID: 25087941 DOI: 10.1016/j.jamcollsurg.2014.01.069]

20 **Duffy A**, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH, O'Reilly EM. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). *J Surg Oncol* 2008; **98**: 485-489 [PMID: 18802958 DOI: 10.1002/jso.21141]

21 **Hueman MT**, Vollmer CM Jr, Pawlik TM. Evolving treatment strategies for gallbladder cancer. *Ann Surg Oncol* 2009; **16**: 2101-2115 [PMID: 19495882 DOI: 10.1245/s10434-009-0538-x]

22 **Mizuno T**, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Ando M, Nagino M. Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. *Br J Surg* 2019; **106**: 626-635 [PMID: 30762874 DOI: 10.1002/bjs.11088]

**Footnotes**

**Institutional review board statement:** Ethical review and approval was not required for this study since the data used was de-identified and obtained from a participant use file.

**Informed consent statement:** This study is a retrospective review that utilized only de-identified patient data from the American College of Surgeons National Surgical Quality Improvement Program.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** Data was obtained with the permission from the American College of Surgeons NSQIP database. NSQIP data can be obtained at https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 23, 2023

**First decision:** November 9, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Yang L, China; Zhang CW, China **S-Editor:** Lin C **L-Editor:** A **P-Editor:**

**Table 1 Descriptive statistics for patients in the National Surgical Quality Improvement Program hepatectomy targeted dataset diagnosed gallbladder cancer, 2015-2019, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **No neoadjuvant chemotherapy (*n* = 400)** | **Neoadjuvant chemotherapy (*n* = 52)** | ***P* value** |
| Sex |  |  | 0.72 |
| Female | 267 (59.1) | 36 (8.0) |  |
| Male | 133 (29.4) | 16 (3.5) |  |
| Race |  |  | 0.70 |
| White | 241 (53.3) | 35 (7.7) |  |
| Black or African American | 38 (8.4) | 4 (0.9) |  |
| Asian | 30 (6.6) | 5 (1.1) |  |
| Other | 2 (0.5) | 0 (0) |  |
| Unknown/Not reported | 89 (19.7) | 8 (1.8) |  |
| Ethnicity |  |  | 0.19 |
| Not Hispanic | 293 (64.8) | 41 (9.1) |  |
| Hispanic | 39 (8.6) | 7 (1.6) |  |
| Unknown/not reported | 68 (15.0) | 4 (0.9) |  |
| Diabetes  | 93 (20.6) | 8 (1.8) | 0.20 |
| History of smoking  | 43 (9.5) | 3 (0.7) | 0.26 |
| Dyspnea | 19 (4.2) | 2 (0.4) | 1.00 |
| History of chronic obstructive pulmonary disease | 19(4.2) | 2 (0.4) | 1.00 |
| History of congestive heart failure | 3 (0.7) | 0 (0.0) | 1.00 |
| Hypertension requiring medication | 238 (52.7) | 24 (5.3) | 0.07 |
| Steroid use for chronic condition  | 9 (2.0) | 2 (0.4) | 0.37 |
| > 10% loss body weight in last 6 mo | 19 (4.2) | 5 (1.1) | 0.18 |
| Biliary stent (Yes) | 46 (10.3) | 6 (1.3) | 0.97 |
| T (tumor) stage |  |  | 0.91 |
| T0 & T1 | 43 (9.5) | 6 (1.3) |  |
| T2 | 140 (31.0) | 17 (3.8) |  |
| T3 & T4 | 136 (30.1) | 21 (4.7) |  |
| Tx & Unknown | 68 (15.0) | 7 (1.5) |  |
| N/A | 13 (2.9) | 1 (0.2) |  |
| N (node) stage |  |  | 0.24 |
| N0 | 147 (32.5) | 14 (3.1) |  |
| N1&N2 | 122 (27.0) | 23 (5.1) |  |
| Nx & unknown | 115 (25.5) | 14 (3.1) |  |
| N/A | 16 (3.5) | 1 (0.2) |  |
| M (metastasis) stage |  |  | 0.61 |
| M0/Mx | 224 (50.0) | 34 (7.5) |  |
| M1 | 21 (4.6) | 3 (0.7) |  |
| Unknown | 95 (21.0) | 9 (2.0) |  |
| N/A | 60 (13.3) | 6 (1.3) |  |
|  | Mean (SD) | Mean (SD) |  |
| Age | 67.0 (10.6) | 64.6 (9.1) | 0.07 |
| Pre-operative serum albumin | 3.9 (0.6) | 3.9 (0.5) | 0.65 |
| Pre-operative total bilirubin | 0.8 (1.2) | 0.4 (0.2) | < 0.01 |
| Pre-operative BUN | 15.0 (6.0) | 16.1(6.8) | 0.33 |
| Pre-operative serum creatinine | 0.9 (0.3) | 0.9 (0.3) | 0.45 |
| Pre-operative INR  | 1.0 (0.1) | 1.0 (0.1) | 0.66 |

*P* values are the result of Chi-square, Fisher’s exact, and Wilcoxon rank sum test. INR: International normalized ratio of prothrombin time; BUN: Blood urea nitrogen; N/A: Note available.

**Table 2 Odds ratios for 30-day postoperative complications among patients with gallbladder cancer who underwent neoadjuvant chemotherapy (*n* = 4111)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Primary outcome2** | **Odds ratio** | **95% confidence Interval** | ***P* value** |
| Post-operative bile leak | 0.69 | 0.16, 2.10 | 0.55 |
| Secondary outcomes3 |  |  |  |
| Required blood transfusion | 1.80 | 0.83, 3.61 | 0.11 |
| On the ventilator > 48 h | 3.96 | 0.54, 20.83 | 0.12 |
| Length of ICU stay | 1.09 | 0.97, 1.22  | 0.12 |
| Readmission | 0.68 | 0.23, 1.64 | 0.44 |
| Superficial incisional wound infection | 0.58 | 0.03, 3.02 | 0.61 |
| Organ space wound infection | 0.63 | 0.18, 1.63 | 0.39 |
| Required secondary intervention  | 0.41 | 0.10, 1.17 | 0.15 |
| Conversion rate to open | 1.67 | 0.47, 4.67 | 0.37 |
| Need for biliary reconstruction | 1.15 | 0.54, 2.27 | 0.70 |

1Patientswith missing data were omitted from analysis.

2Adjusted odds ratio with the model including the primary predictor (neoadjuvant chemotherapy) and potential confounders (race, ethnicity, placement of a biliary stent, and preoperative bilirubin).

3Unadjusted odds ratios.

Comparison group is patients having surgery for gallbladder cancer without neoadjuvant chemotherapy. ICU: Intensive care unit.